In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next generation sequencing.

Reach out to our experts & discover how we can help you transform research and advance health

Contact Us

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

• Jérôme Sallette, PhD, CSO Cerba Research
• Shu Jen Chen, PhD, CSO ACT Genomics
• Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
• George Wei, PhD, Vice President R&D ACT Genomics
• Renaud Burrer, PhD, Head of Histopathology Cerba Research
• Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Flyer – Patient Connect

Click here to download the flyer

Reach out to our experts  and discover how we can help you advance your clinical research

Contact Us

Did you know that Cerba Research was present in Australia?

Click here to download the fact sheet

Reach out to our experts and discover how we can help you advance your research

Contact Us

Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.

Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.

At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.

Brochure – Cerba Research's Multi-Omics Approaches in Hematological Malignancies

Click here to download the brochure

Reach out to our experts and discover how we can help you advance your research

Contact Us

A biorepository enabled by a leading medical diagnostic and healthcare infrastructure

Since 1967, Cerba HealthCare Group has accompanied scientific and technological advances in diagnosis, prevention and precision medicine in order to better meet the expectations of health professionals and patients. This constant quest for improvement has led Cerba Research to create one of the world’ s largest and multinational commercial biorepository with the unique goal of contributing to the advancement of Science.

As a specialty and central laboratory for clinical trials covering 5 continents, our biospecimen provision is the starting point for your research to facilitate further downstream decisions inclusion: robust assay development and assay validation with quality samples.

Click here to download the Cerba Research biorepository brochure

Click here to download the brochure

Reach out to our experts and discover how we can help you advance your research

Contact Us

PBMC-based analytical tests are crucial to accelerating the development of new vaccines, drug discovery, diagnostic development, Precision Medicine Research (e.g., CAR-T cell therapy, gene therapy, etc.), and toxicology applications. To this end, the supply of high-quality PBMC is an essential first step in the process.

Brochure – Processing Peripheral Blood Mononuclear Cells (PBMC) For Clinical Trials

Click here to download the brochure

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us

Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow

Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.

Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhances access to data. The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.

Watch the recording of this webinar to learn more about patient recruitment for decentralized clinical trials.

Reach out to our experts and discover how we can help you advance your clinical trials

Contact Us

The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine and genetic studies.

To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.

Watch this webinar and discover the answers to these questions:

• Did we succeed, how fast did we adapt and are we ready to face a new pandemic crisis in the future?
• How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?

Reach out to our experts and discover how  we can help you advance your clinical trial

Contact Us

Pharmaceutical and biotech companies are dealing with a paradigm shift in drug development as the industry embraces more personalized, complex, and expensive cell therapies.

With some therapeutics proving ineffective in as many as 75% of patients, the need for precision medicine is clear, as is the benefit of using selection biomarkers in the drug development process where success rates can triple. Consequently, companies are balancing the increased demands for unique, esoteric testing with budget restrictions and geographical coverage.

In the quest to accelerate drug discovery to market and reduce costs, the industry continues ever further with externalization and outsourcing of drug development. Outsourcing penetration is expected to expand, as pharmaceutical and biotech companies must continue to replenish their pipeline and, hence, are incessantly looking for new sources of innovation.

Read the full article here

Reach out to our experts to discover how we can help advance your clinical trial

Contact Us